114 related articles for article (PubMed ID: 3253181)
1. [Alteration of platelet function in myeloproliferative disorder and its clinical significance].
Ni HY; Deng CG; Ruan HF; Pam CF; Li HR; Gon DQ
Hua Xi Yi Ke Da Xue Xue Bao; 1988 Sep; 19(3):312-6. PubMed ID: 3253181
[No Abstract] [Full Text] [Related]
2. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
3. Hematopathologic findings in the myeloproliferative disorders.
Dickstein JI; Vardiman JW
Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
[TBL] [Abstract][Full Text] [Related]
4. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders.
Brodsky I; Kahn SB; Ross EM; Petkov G
Cancer; 1972 Dec; 30(6):1444-50. PubMed ID: 4509103
[No Abstract] [Full Text] [Related]
5. Platelet defects in the myeloproliferative disorders.
Inceman S; Tangün Y
Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
[No Abstract] [Full Text] [Related]
6. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
Murphy S; Davis JL; Walsh PN; Gardner FH
Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
[TBL] [Abstract][Full Text] [Related]
7. Platelet aggregation and platelet factor 3 activity in myeloproliferative disorders.
Tangün Y
Thromb Diath Haemorrh; 1971 Jun; 25(2):241-51. PubMed ID: 5284903
[No Abstract] [Full Text] [Related]
8. A prospective study of haemostatic parameters in relation to the clinical course of myeloproliferative disorders.
Wehmeier A; Fricke S; Scharf RE; Schneider W
Eur J Haematol; 1990 Oct; 45(4):191-7. PubMed ID: 2146144
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous platelet aggregation in myeloproliferative disorders. A preliminary study.
Barbui T; Battista R; Dini E
Acta Haematol; 1973; 50(1):25-9. PubMed ID: 4200801
[No Abstract] [Full Text] [Related]
10. Generation of arachidonic acid metabolites from stimulated whole blood in patients with chronic myeloproliferative disorders.
Parise P; Huybrechts E; Grasselli S; Falcinelli F; Nenci GG; Gresele P; Vermylen J
Acta Haematol; 1991; 85(2):88-92. PubMed ID: 1902615
[TBL] [Abstract][Full Text] [Related]
11. Influence of thrombopoietin on platelet activation in myeloproliferative disorders.
Usuki K; Iki S; Endo M; Izutsu K; Inoue K; Nishimura T; Urabe A
Br J Haematol; 1997 Jun; 97(3):530-7. PubMed ID: 9207394
[TBL] [Abstract][Full Text] [Related]
12. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
[TBL] [Abstract][Full Text] [Related]
13. Myeloproliferative disorders. Classification and diagnostic features with special emphasis on chronic myelogenous leukemia and agnogenic myeloid metaplasia.
Hyun BH; Gulati GL; Ashton JK
Clin Lab Med; 1990 Dec; 10(4):825-38. PubMed ID: 2272176
[TBL] [Abstract][Full Text] [Related]
14. Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis.
Mitterbauer G; Winkler K; Gisslinger H; Geissler K; Lechner K; Mannhalter C
Am J Clin Pathol; 1999 Jul; 112(1):93-100. PubMed ID: 10396290
[TBL] [Abstract][Full Text] [Related]
15. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
[TBL] [Abstract][Full Text] [Related]
16. Platelet aggregation in platelet-rich plasma and whole blood in 120 patients with myeloproliferative disorders.
Balduini CL; Bertolino G; Noris P; Piletta GC
Am J Clin Pathol; 1991 Jan; 95(1):82-6. PubMed ID: 1987755
[TBL] [Abstract][Full Text] [Related]
17. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder.
Handa M; Watanabe K; Kawai Y; Kamata T; Koyama T; Nagai H; Ikeda Y
Thromb Haemost; 1995 Mar; 73(3):521-8. PubMed ID: 7667837
[TBL] [Abstract][Full Text] [Related]
18. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis.
Burstein SA; Malpass TW; Yee E; Kadin M; Brigden M; Adamson JW; Harker LA
Br J Haematol; 1984 Jul; 57(3):383-92. PubMed ID: 6743563
[TBL] [Abstract][Full Text] [Related]
19. [Platelet function in chronic myeloproliferative syndromes associated with thrombocytosis].
Grebe G; Pereira J; Mezzano D; Legues ME; Aranda E; Lira P
Rev Med Chil; 1985 Jan; 113(1):32-7. PubMed ID: 4081383
[No Abstract] [Full Text] [Related]
20. Blood platelet calcium content and aggregation behaviour in myeloproliferative disorders and secondary thrombocytosis.
Mindner K; Ostermann G; Hochhaus A; Höche D; Till U
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):461-4. PubMed ID: 2465953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
